Leerink analyst Seamus Fernandez says the data from two Phase 2 Acceleron's luspatercept extension trials from the European Hematology Association annual meeting show "impressive" reduction in transfusion burden and sustained increases in hemoglobin out to 15 months in low-risk myelodysplastic syndrome, or MDS, and 12 months in beta-thalassemia. Fernandez continues to look forward to key catalysts near the end of the year, when the company is expected to release initial data from treatment-naive and ringed sideroblast-negative MDS patients and topline results from part 2 of the Phase 2 DART study in renal cell carcinoma. The analyst reiterates an Outperform rating and $50 price target on the shares.